This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Company

Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss

Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.


Video courtesy of British Business Bank’s Business Finance Guide.

https://www.youtube.com/embed/rUzMSpyJrlc

About Exonate

Exonate is a privately held, early stage, biotech, company spun out of the University of Nottingham
that is focused on Vascular Endothelial Growth Factor (VEGF). The Company has grown
significantly in the last year as it welcomes investment and input from an increasing Global
market.

It aspires to successfully deliver medicines in areas of unmet need, by targeting diseases through
regulation of VEGF isoforms/variants that are both protective and disease promoting. Exonate’s
lead program is focused on wet Age-Related Macular Degeneration, (wet AMD), which is the
leading cause of vision loss in people aged 60 and older. The Company is founded on scientific
excellence with strong links to Prof. David Bates and his lab at Nottingham University
specialising in the biology and biochemical pathways of VEGF splice variants. In addition Exonate
has formed academic collaborations with the university of New South Wales (Australia) and
Professor Jonathan Morris.

Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through
selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These
inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet
AMD.

Exonate is led by an experienced, international management team that has worked together
previously, successfully raising capital for start-ups and early stage companies over many years.
Exonate’s management has cross-disciplinary experience in medicine, finance, drug development
and the pharmaceutical and biotech industries. CEO Catherine Beech, has over 25 years
biotech/pharma experience including 12 years in big pharma leading development programs in
cardiovascular, Parkinson’s disease and HIV.

Our History

Feb 2014

Nottingham Angels and Fusion IP make first investment in University spin-out business, Exonate

Dec 2015

Dr Chris Torrance joins the Exonate Board of Directors Prof Pete Adamson and Prof Usha Chakravarthy join the Exonate CAB

Meet our team

Oct 2015

Exonate closes 2nd successful funding round

Apr 2016

Dr Jenny Batson awarded the David Meyer Research Prize

Nov 2016

Exonate closes 3rd successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)

John Kurek Uniseed joins the Exonate Board of Directors

Meet John Kurek

Dec 2016

Exonate Cambridge moves to larger premises

Jan 2017

Exonate turns 3! Andy Baxter joins as Head of Product Development

Meet Andy Baxter

Feb 2017

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

See our investors

Jul 2017

Exonate is the ‘One to Watch’ in the Best Investment in Life Sciences

Nov 2017

Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)

Meet the team

Jan 2018

Exonate nominates compounds for clinical development

Experienced and international team

Our strength is scientific expertise with cross-disciplinary experience in medicine and drug development, alongside a track record of raising capital for early stage companies. Our work is supported by highly respected Clinical and Scientific Advisory boards made up of leading international Key Opinion Leaders (KOLs) from the ophthalmology industry.

Exonate is a strong well-funded business

As an early stage biotechnology company, we are a strong, well-funded International business, with a number of Blue-chip investors.